{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:26:33Z","timestamp":1740108393314,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of the Basque Country UPV\/EHU","award":["GIU17\/32"],"award-info":[{"award-number":["GIU17\/32"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10096-021-04255-w","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:05:41Z","timestamp":1620086741000},"page":"2145-2152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic\/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain"],"prefix":"10.1007","volume":"40","author":[{"given":"Maitane","family":"Ibar-Bariain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantxazu","family":"Isla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Solin\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Sanz-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Canut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-6385","authenticated-orcid":false,"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"4255_CR1","doi-asserted-by":"publisher","first-page":"1900457","DOI":"10.2807\/1560-7917.ES.2020.25.16.1900457","volume":"25","author":"A Gonz\u00e1lez-D\u00edaz","year":"2020","unstructured":"Gonz\u00e1lez-D\u00edaz A, Machado MP, C\u00e0mara J, Yuste J, Varon E, Domenech M et al (2020) Two multi-fragment recombination events resulted in the \u03b2-lactam-resistant serotype 11A-ST6521 related to Spain 9V-ST156 pneumococcal clone spreading in south-western Europe, 2008 to 2016. Eurosurveill 25:1900457. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.16.1900457","journal-title":"Eurosurveill"},{"key":"4255_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.eimc.2014.05.011","volume":"33","author":"LR Ciancotti-Oliver","year":"2015","unstructured":"Ciancotti-Oliver LR, Huertas-Zarco I, P\u00e9rez-P\u00e9rez E, Carmona-Mart\u00ed E, Carb\u00f3-Malonda R, Gil-Bru A et al (2015) Invasive pneumococcal disease in the Community of Valencia. Six years of surveillance (2007-2012). Enferm Infecc Microbiol Clin 33:149\u2013155. https:\/\/doi.org\/10.1016\/j.eimc.2014.05.011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.eimc.2017.10.026","volume":"36","author":"P Latasa-Zamalloa","year":"2018","unstructured":"Latasa-Zamalloa P, Sanz-Moreno JC, Ordob\u00e1s-Gav\u00edn M, Barranco-Ordo\u00f1ez MD, Ins\u00faa-Marisquerena E, Gil-de-Miguel A et al (2018) Trends of invasive pneumococcal disease and its serotypes in the Autonomous Community of Madrid. Enferm Infecc Microbiol Clin 36:612\u2013620. https:\/\/doi.org\/10.1016\/j.eimc.2017.10.026","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eimc.2015.01.010","volume":"33","author":"S M\u00e9ndez-Lage","year":"2015","unstructured":"M\u00e9ndez-Lage S, Losada-Castillo I, Agulla-Budi\u00f1o A (2015) Streptococcus pneumoniae: serotype distribution, antimicrobial susceptibility, risk factors and mortality in Galicia over a two year-period. Enferm Infecc Microbiol Clin 33:579\u2013584. https:\/\/doi.org\/10.1016\/j.eimc.2015.01.010","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"20","key":"4255_CR5","doi-asserted-by":"publisher","first-page":"30050","DOI":"10.1016\/j.eimc.2020.02.016","volume":"S0213-005X","author":"JM Marimon","year":"2020","unstructured":"Marimon JM, Ardanuy C (2020) Epidemiology of pneumococcal diseases in Spain after the introduction of pneumococcal conjugate vaccines. Enferm Infecc Microbiol Clin S0213-005X(20):30050\u201330051. https:\/\/doi.org\/10.1016\/j.eimc.2020.02.016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR6","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.vaccine.2011.05.099","volume":"29","author":"MA Gutierrez-Rodr\u00edguez","year":"2011","unstructured":"Gutierrez-Rodr\u00edguez MA, Varela-Gonz\u00e1lez A, Ordov\u00e1s-Gav\u00edn MA, Mart\u00edn-Mart\u00ednez F, Garc\u00eda-Mar\u00edn N, Ramos-Bl\u00e1zquez B et al (2011) Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine 29:5740\u20135746. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.099","journal-title":"Vaccine"},{"key":"4255_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1469-0691.2010.03182.x","volume":"16","author":"J Li\u00f1ares","year":"2010","unstructured":"Li\u00f1ares J, Ardanuy C, Pallares R, Fenoll A (2010) Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 16:402\u2013410. https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03182.x","journal-title":"Clin Microbiol Infect"},{"key":"4255_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1128\/JCM.01454-08","volume":"47","author":"A Fenoll","year":"2009","unstructured":"Fenoll A, Granizo JJ, Aguilar L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G et al (2009) Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47:1012\u20131020. https:\/\/doi.org\/10.1128\/JCM.01454-08","journal-title":"J Clin Microbiol"},{"key":"4255_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cmi.2019.10.034","volume":"26","author":"A Gonzalez-D\u00edaz","year":"2020","unstructured":"Gonzalez-D\u00edaz A, C\u00e0mara J, Ercibengoa M, Cercenado E, Larrosa N, Quesada MD, Fontanals D, Cubero M, Marim\u00f3n JM, Yuste J, Ardanuy C (2020) Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain. Clin Microbiol Infect 26:753\u2013759 https:\/\/10.1016\/j.cmi.2019.10.034","journal-title":"Clin Microbiol Infect"},{"key":"4255_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","volume":"21","author":"E As\u00edn-Prieto","year":"2015","unstructured":"As\u00edn-Prieto E, Rodr\u00edguez-Gasc\u00f3n A, Isla A (2015) Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents. J Infect Chemother 21:319\u2013329. https:\/\/doi.org\/10.1016\/j.jiac.2015.02.001","journal-title":"J Infect Chemother"},{"key":"4255_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55:601\u2013607. https:\/\/doi.org\/10.1093\/jac\/dki079","journal-title":"J Antimicrob Chemother"},{"key":"4255_CR12","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2020) Breakpoint tables for interpretation of MICs and zone diameters (V 10.0). http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf. Accessed 7 December 2020"},{"key":"4255_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40780-016-0043-x","volume":"2","author":"T Komatsu","year":"2016","unstructured":"Komatsu T, Inomata T, Watanabe I, Kobayashi M, Kokubun H, Ako J et al (2016) Population pharmacokinetic analysis and dosing regimen optimization of penicillin G in patients with infective endocarditis. JJ Pharm Health Care Sci 2:9. https:\/\/doi.org\/10.1186\/s40780-016-0043-x","journal-title":"JJ Pharm Health Care Sci"},{"key":"4255_CR14","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2010) Cefotaxime: rationale for the clinical breakpoints, version 1.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Cefotaxime_Rationale_Document_1.0_2010Nov.pdf. Accessed 7 December 2020"},{"key":"4255_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1128\/AAC.42.4.88516","volume":"42","author":"SC Chien","year":"1998","unstructured":"Chien SC, Wong FA, Fowler CL, Callery-D\u2019Amico SV, Williams RR, Nayak R et al (1998) Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 42:885\u2013888. https:\/\/doi.org\/10.1128\/AAC.42.4.88516","journal-title":"Antimicrob Agents Chemother"},{"key":"4255_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","volume":"64","author":"NA Kratochwil","year":"2002","unstructured":"Kratochwil NA, Huber W, M\u00fcller F, Kansy M, Gerber PR (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64:1355\u20131374. https:\/\/doi.org\/10.1016\/S0006-2952(02)01074-2","journal-title":"Biochem Pharmacol"},{"key":"4255_CR17","first-page":"01","volume":"31","author":"JM Cabrera-Maqueda","year":"2018","unstructured":"Cabrera-Maqueda JM, Fuentes-Rum\u00ed L, Valero-L\u00f3pez G, Baidez-Guerrero AE, Garc\u00eda-Molina E, D\u00edaz-P\u00e9rez J et al (2018) Antibiotic diffusion to central nervous system. Rev Esp Quimioter 31:01\u201312","journal-title":"Rev Esp Quimioter"},{"key":"4255_CR18","doi-asserted-by":"publisher","first-page":"289e300","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2:289e300. https:\/\/doi.org\/10.1038\/nrmicro862","journal-title":"Nat Rev Microbiol"},{"key":"4255_CR19","first-page":"121","volume":"32","author":"M Ibar-Bariain","year":"2019","unstructured":"Ibar-Bariain M, Rodriguez-Gasc\u00f3n A, Isla A, Solin\u00eds MA, Canut-Blasco A (2019) Application of pharmacokinetic\/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine. Rev Esp Quimioter 32:121\u2013129","journal-title":"Rev Esp Quimioter"},{"issue":"20","key":"4255_CR20","doi-asserted-by":"publisher","first-page":"30224","DOI":"10.1016\/j.eimc.2020.05.025","volume":"S0213-005X","author":"M Ibar-Bariain","year":"2020","unstructured":"Ibar-Bariain M, Rodr\u00edguez-Gasc\u00f3n A, Isla A, Solin\u00eds M\u00c1, Canut-Blasco A (2020) Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: a pharmacokinetic\/pharmacodynamic perspective. Enferm Infecc Microbiol Clin S0213-005X(20):30224\u20133022X. https:\/\/doi.org\/10.1016\/j.eimc.2020.05.025","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40121-019-0243-4","volume":"8","author":"A Cristinacce","year":"2019","unstructured":"Cristinacce A, Wright JG, Stone GG, Hammond J, McFadyen L, Raber S (2019) A retrospective analysis of probability of target attainment in community-acquired pneumonia: ceftaroline fosamil versus comparators. Infect Dis Ther 8:185\u2013198. https:\/\/doi.org\/10.1007\/s40121-019-0243-4","journal-title":"Infect Dis Ther"},{"key":"4255_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ijantimicag.2014.12.023","volume":"45","author":"A Canut","year":"2015","unstructured":"Canut A, Isla A, Rodr\u00edguez-Gasc\u00f3n A (2015) Pharmacokinetic\/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 45:399\u2013405. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.023","journal-title":"Int J Antimicrob Agents"},{"key":"4255_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijantimicag.2012.06.005","volume":"40","author":"E As\u00edn","year":"2012","unstructured":"As\u00edn E, Isla A, Canut A, Rodr\u00edguez Gasc\u00f3n A (2012) Comparison of antimicrobial pharmacokinetic\/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 40:313\u2013322. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.06.005","journal-title":"Int J Antimicrob Agents"},{"key":"4255_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcrc.2018.11.016","volume":"50","author":"H Barrasa","year":"2019","unstructured":"Barrasa H, Soraluce A, Isla A, Mart\u00edn A, Maynar J, Canut A et al (2019) Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK\/PD target attainment. J Crit Care 50:69\u201376. https:\/\/doi.org\/10.1016\/j.jcrc.2018.11.016","journal-title":"J Crit Care"},{"key":"4255_CR25","doi-asserted-by":"publisher","unstructured":"de Miguel S, Domenech M, Gonz\u00e1lez-Camacho F, Sempere J, Vicioso D, Sanz JC et al (2020) Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era. Clin Infect Dis.ciaa1483. https:\/\/doi.org\/10.1093\/cid\/ciaa1483","DOI":"10.1093\/cid\/ciaa1483"},{"key":"4255_CR26","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1017\/S0950268820002708","volume":"148","author":"C Izquierdo","year":"2020","unstructured":"Izquierdo C, Ciruela P, Hern\u00e1ndez S, Garc\u00eda-Garc\u00eda JJ, Esteva C, Moraga-Llop F et al (2020) Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era. Epidemiol Infect 148:e279. https:\/\/doi.org\/10.1017\/S0950268820002708","journal-title":"Epidemiol Infect"},{"key":"4255_CR27","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1016\/j.vaccine.2017.06.070","volume":"35 Pt B","author":"J Ruiz-Contreras","year":"2017","unstructured":"Ruiz-Contreras J, Picazo J, Casado-Flores J, Baquero-Artigao F, Hern\u00e1ndez-Sampelayo T, Otheo E et al (2017) Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine 35 Pt B:4646\u20134651. https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.070","journal-title":"Vaccine"},{"key":"4255_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3201\/eid2306.161331","volume":"23","author":"CP Andam","year":"2017","unstructured":"Andam CP, Worby CJ, Gierke R, McGee L, Pilishvili T, Hanage WP (2017) Penicillin resistance of nonvaccine type pneumococcus before and after PCV13 introduction, United States. Emerg Infect Dis 23:1012\u20131015. https:\/\/doi.org\/10.3201\/eid2306.161331","journal-title":"Emerg Infect Dis"},{"key":"4255_CR29","doi-asserted-by":"publisher","unstructured":"Isea-Pe\u00f1a MC, Sanz-Moreno JC, Esteban J, Fern\u00e1ndez-Roblas R, Fern\u00e1ndez-Guerrero ML Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection 41:935\u2013939. https:\/\/doi.org\/10.1007\/s15010-013-0481-4","DOI":"10.1007\/s15010-013-0481-4"},{"key":"4255_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijmm.2017.04.003","volume":"307","author":"J Schmitz","year":"2017","unstructured":"Schmitz J, van der Linden M, Al-Lahham A, Levina N, Pletz MW, Im\u00f6hl M (2017) Fluoroquinolone resistance in Streptococcus pneumoniae isolates in Germany from 2004-2005 to 2014-2015. Int J Med Microbiol 307:216\u2013222. https:\/\/doi.org\/10.1016\/j.ijmm.2017.04.003","journal-title":"Int J Med Microbiol"},{"key":"4255_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jmii.2016.05.003","volume":"50","author":"HH Chen","year":"2017","unstructured":"Chen HH, Li HC, Su LH, Chiu CH (2017) Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era. J Microbiol Immunol Infect 50:839\u2013845. https:\/\/doi.org\/10.1016\/j.jmii.2016.05.003","journal-title":"J Microbiol Immunol Infect"},{"key":"4255_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3201\/eid1506.080684","volume":"15","author":"AG De-la-Campa","year":"2009","unstructured":"De-la-Campa AG, Ardanuy C, Balsalobre L, P\u00e9rez-Trallero E, Marim\u00f3n JM, Fenoll A et al (2009) Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 15:905\u2013911. https:\/\/doi.org\/10.3201\/eid1506.080684","journal-title":"Emerg Infect Dis"},{"key":"4255_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.eimc.2019.05.006","volume":"38","author":"JC Sanz","year":"2020","unstructured":"Sanz JC, Rodr\u00edguez-Avial I, R\u00edos E, Garc\u00eda-Comas L, Ordob\u00e1s M, Cercenado E (2020) Increase of serotype 8, ST53 clone, as the prevalent strain of Streptococcus pneumoniae causing invasive disease in Madrid, Spain (2012\u20132015). Enferm Infecc Microbiol Clin 38:105\u2013110. https:\/\/doi.org\/10.1016\/j.eimc.2019.05.006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR34","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2021) Breakpoint tables for interpretation of MICs and zone diameters (V 11.0). http:\/\/www.eucast.org. Accessed 8 December 2020"},{"key":"4255_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.eimc.2018.10.013","volume":"37","author":"A Valero","year":"2019","unstructured":"Valero A, Isla A, Rodr\u00edguez-Gasc\u00f3n A, Calvo B, Canut A, Solin\u00eds M\u00c1 (2019) Pharmacokinetic\/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients. Enferm Infecc Microbiol Clin 37:380\u2013386. https:\/\/doi.org\/10.1016\/j.eimc.2018.10.013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.eimc.2019.02.009","volume":"37","author":"A Valero","year":"2019","unstructured":"Valero A, Isla A, Rodr\u00edguez-Gasc\u00f3n A, Canut A, \u00c1ngeles Solin\u00eds M (2019) Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK\/PD analysis: an 18-year surveillance study. Enferm Infecc Microbiol Clin 37:626\u2013633. https:\/\/doi.org\/10.1016\/j.eimc.2019.02.009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"4255_CR37","unstructured":"European Centre for Disease Prevention and Control (ECDC). Available on: https:\/\/www.ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/ears-net. Accessed 7 December 2020"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04255-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T10:11:23Z","timestamp":1631959883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04255-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4255"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04255-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}